Here's something for you all to think about.
SP is proceeding with an ADHD trial with an inferior molecule that has a very short patent life in a field that is not covered by their Agreement with Cortex. Why is that?
Do you really think that this is happening without the collaboration and blessing of Cortex? If SP was just winging it without COR's blessing, where are they going to get the molecule that has a patent life that will actually make them money? The answer is only at Cortex.
Also, if SP didn't have COR's blessing, Cortex could cut a deal on the cheap with a SP competitor and give them CX701 to start ADHD trials with the promise of providing them the next low impact molecule available in order to undermine SP's renegade behavior.
So, in conclusion, it is VERY unlikely that SP is proceeding down the ADHD avenue WITHOUT Cortex's full support and blessing. Which leads to either a new deal with SP for the ADHD indication AND the next available low impact molecule available so they can actually have a molecule with a patent life that would be profitable, or a buy out.
This stock was north of $6 per share based on ADHD approval. We now have obtained a partner to carry ADHD forward who has the monetary and physical resources necessary to deal with the FDA and accomplish it.
In my opinion, the paperwork just has not been "signed" yet. That's what I'm seeing.
Cordially,
RBlatch
PS: The "mo mo boys" are STILL not here yet. Just look at the recent volumn.
